|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM377182419 |
| 003 |
DE-627 |
| 005 |
20250306150000.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240905s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.3928/23258160-20240729-03
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1256.xml
|
| 035 |
|
|
|a (DE-627)NLM377182419
|
| 035 |
|
|
|a (NLM)39231114
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Jeong, Hejin
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Investigating the Relationship Between Lipid-Lowering Agents and the Complications of Diabetic Retinopathy
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 16.12.2024
|
| 500 |
|
|
|a Date Revised 16.12.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a BACKGROUND AND OBJECTIVE: As the therapeutic efficacy of lipid-lowering agents (LLA) against diabetic retinopathy (DR) remains controversial, this study aimed to evaluate whether various LLA therapies are associated with a reduced risk of DR progression
|
| 520 |
|
|
|a PATIENTS AND METHODS: This retrospective study of the medical records of adults with type 2 diabetes mellitus and DR compared the risk of adverse progression of DR between patients who received statins, fibrates, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and no LLA (control)
|
| 520 |
|
|
|a RESULTS: Patients in the statin cohort had a reduced rate of progression to proliferative DR compared to controls (HR = 0.30, CI = 0.11 to 0.83). The PCSK9 inhibitor cohort had a reduced risk of progressing to other secondary complications of DR compared to the control (RR = 0.52, CI = 0.43 to 0.64), statin (RR = 0.69, CI = 0.61 to 0.79), and fibrate (RR = 0.67, CI = 0.59 to 0.77) cohorts
|
| 520 |
|
|
|a CONCLUSIONS: These findings suggest use of statins and PCSK9 inhibitors are associated with a reduced risk of adverse progression of DR. [Ophthalmic Surg Lasers Imaging Retina 2024;55:706-713.]
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Hypolipidemic Agents
|2 NLM
|
| 650 |
|
7 |
|a Hydroxymethylglutaryl-CoA Reductase Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a PCSK9 Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Fibric Acids
|2 NLM
|
| 700 |
1 |
|
|a Shaia, Jacqueline K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Talcott, Katherine E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Singh, Rishi P
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Ophthalmic surgery, lasers & imaging retina
|d 2013
|g 55(2024), 12 vom: 01. Dez., Seite 706-713
|w (DE-627)NLM224956647
|x 2325-8179
|7 nnas
|
| 773 |
1 |
8 |
|g volume:55
|g year:2024
|g number:12
|g day:01
|g month:12
|g pages:706-713
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.3928/23258160-20240729-03
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_63
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_90
|
| 912 |
|
|
|a GBV_ILN_91
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_135
|
| 912 |
|
|
|a GBV_ILN_136
|
| 912 |
|
|
|a GBV_ILN_151
|
| 912 |
|
|
|a GBV_ILN_181
|
| 912 |
|
|
|a GBV_ILN_203
|
| 912 |
|
|
|a GBV_ILN_217
|
| 912 |
|
|
|a GBV_ILN_235
|
| 912 |
|
|
|a GBV_ILN_289
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_297
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_352
|
| 912 |
|
|
|a GBV_ILN_674
|
| 912 |
|
|
|a GBV_ILN_676
|
| 912 |
|
|
|a GBV_ILN_688
|
| 912 |
|
|
|a GBV_ILN_698
|
| 912 |
|
|
|a GBV_ILN_721
|
| 912 |
|
|
|a GBV_ILN_737
|
| 912 |
|
|
|a GBV_ILN_791
|
| 912 |
|
|
|a GBV_ILN_812
|
| 912 |
|
|
|a GBV_ILN_1127
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 55
|j 2024
|e 12
|b 01
|c 12
|h 706-713
|